- Home
- KURA
KURA
Kura Oncology Inc.
as 06-30-2025 2:31pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 561.9M | IPO Year: | N/A |
| Target Price: | $24.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $23.48 | Next Earning Date: | 08-07-2025 |
| Revenue: | $67,991,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 109.86% | Revenue Growth (next year): | 107.90% |
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bair Teresa Brophy | KURA | Chief Legal Officer | May 19 '25 | Sell | $5.96 | 1,559 | $9,291.64 | 107,948 | |
| FORD KATHLEEN | KURA | Chief Operating Officer | May 19 '25 | Sell | $6.28 | 1,558 | $9,777.38 | 21,367 |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
Zacks
18 days ago
Is the Options Market Predicting a Spike in Kura Oncology Stock?
MT Newswires
18 days ago
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia
GlobeNewswire
19 days ago
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
Zacks
24 days ago
KURA Stock Rises More Than 15% This Past Week: Here's Why
GlobeNewswire
25 days ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
MT Newswires
a month ago
Kura Oncology, Kyowa Get FDA Acceptance, Priority Review of New Drug Application for Ziftomenib
GlobeNewswire
a month ago
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.